Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2010 (2010), Article ID 576384, 7 pages
http://dx.doi.org/10.1155/2010/576384
Review Article

Angiogenesis and Breast Cancer

1Laboratory of Medical Investigation (LIM) , School of Medicine, University of São Paulo, 01246-903 São Paulo-SP, Brazil
2School of Health Sciences, Life and Health Sciences Research Institute, University of Minho, Campos of Gualtar, 4710-057 Braga, Portugal
3Institute of Molecular Pathology and Immunology, University of Porto, IPATIMUP, Rua Roberto Frias s/n, 4200 Porto, Portugal
4Medical Faculty, Porto University, 4099-002 Porto, Portugal

Received 12 April 2010; Revised 29 July 2010; Accepted 2 September 2010

Academic Editor: Michael A. Carducci

Copyright © 2010 Adhemar Longatto Filho et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Folkman, E. Merler, C. Abernathy, and G. Williams, “Isolation of a tumor factor responsible or angiogenesis,” Journal of Experimental Medicine, vol. 133, no. 2, pp. 275–288, 1971. View at Google Scholar · View at Scopus
  2. R. S. Kerbel, “Tumor angiogenesis,” The New England Journal of Medicine, vol. 358, no. 19, pp. 2039–2049, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. G. H. Algire, H. W. Chalkley, F. Y. Legallais, and H. D. Park, “Vascular reactions to normal and malignant tissue in vivo. I vascular reactions of mice to wound and to normal and neoplastic transplants,” Journal of the National Cancer Institute, vol. 6, p. 7385, 1945. View at Google Scholar
  4. N. Ferrara, “Vascular endothelial growth factor,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 6, pp. 789–791, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Shibuya, “Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis,” Journal of Biochemistry and Molecular Biology, vol. 41, no. 4, pp. 278–286, 2008. View at Google Scholar · View at Scopus
  6. M. Duarte, A. Longatto Filho, and F. C. Schmitt, “Angiogenesis, haemostasis and cancer: new paradigms and old concerns,” Jornal Brasileiro de Patologia e Medicina Laboratorial, vol. 43, no. 6, pp. 441–449, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Bando, “Vascular endothelial growth factor and bevacitumab in breast cancer,” Breast Cancer, vol. 14, no. 2, pp. 163–173, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Y. Hsu and H. A. Wakelee, “Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy,” BioDrugs, vol. 23, no. 5, pp. 289–304, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. N. R. Smith, D. Baker, N. H. James et al., “Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers,” Clinical Cancer Research, vol. 16, no. 14, pp. 3548–3561, 2010. View at Publisher · View at Google Scholar
  10. E. S. Rennel, A. H. R. Varey, A. J. Churchill et al., “VEGF121b, a new member of the VEGFxxxb family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo,” British Journal of Cancer, vol. 101, no. 7, pp. 1183–1193, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Eichholz, S. Merchant, and A. M. Gaya, “Anti-angiogenesis therapies: their potential in cancer management,” OncoTargets and Therapy, vol. 3, pp. 69–82, 2010. View at Google Scholar
  12. R. J. C. Albuquerque, T. Hayashi, W. G. Cho et al., “Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth,” Nature Medicine, vol. 15, no. 9, pp. 1023–1030, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. K. J. Higgins, S. Liu, M. Abdelrahim et al., “Vascular endothelial growth factor receptor-2 expression is down-regulated by 17β-estradiol in MCF-7 breast cancer cells by estrogen receptor α/Sp proteins,” Molecular Endocrinology, vol. 22, no. 2, pp. 388–402, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. T. H. Lee, S. Seng, M. Sekine et al., “Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1,” PLoS Medicine, vol. 4, no. 6, article e186, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Viacava, A. G. Naccarato, G. Bocci et al., “Angiogenesis and VEGF expression in pre-invasive lesions of the human breast,” Journal of Pathology, vol. 204, no. 2, pp. 140–146, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. A. H. S. Lee, E. A. Dublin, L. G. Bobrow, and R. Poulsom, “Invasive lobular and invasive ductal carcinoma of the breast show distinct patterns of vascular endothelial growth factor expression and angiogenesis,” Journal of Pathology, vol. 185, no. 4, pp. 394–401, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Kawai, H. Li, P. Chun, S. Avraham, and H. K. Avraham, “Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells,” Oncogene, vol. 21, no. 50, pp. 7730–7739, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Guo, Q. Fang, H.-Q. Tao et al., “Overexpression of vascular endothelial growth factor by MCF-7 breast cancer cells promotes estrogen-independent tumor growth in vivo,” Cancer Research, vol. 63, no. 15, pp. 4684–4691, 2003. View at Google Scholar · View at Scopus
  19. M. P. Pinto, M. M. Badtke, M. L. Dudevoir, J. C. Harrell, B. M. Jacobsen, and K. B. Horwitz, “Vascular endothelial growth factor secreted by activated stroma enhances angiogenesis and hormone-independent growth of estrogen receptor-positive breast cancer,” Cancer Research, vol. 70, no. 7, pp. 2655–2664, 2010. View at Publisher · View at Google Scholar
  20. A. Marinho, R. Soares, J. Ferro, M. Lacerda, and F. C. Schmitt, “Angiogenesis in breast cancer is related to age but not to other prognostic parameters,” Pathology Research and Practice, vol. 193, no. 4, pp. 267–273, 1997. View at Google Scholar
  21. N. Weidner, J. P. Semple, W. R. Welch, and J. Folkman, “Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma,” The New England Journal of Medicine, vol. 324, no. 1, pp. 1–8, 1991. View at Google Scholar · View at Scopus
  22. Y. Nakamura, H. Yasuoka, M. Tsujimoto et al., “Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer,” Clinical Cancer Research, vol. 9, no. 14, pp. 5313–5317, 2003. View at Google Scholar · View at Scopus
  23. V. Mumprecht and M. Detmar, “Lymphangiogenesis and cancer metastasis,” Journal of Cellular and Molecular Medicine, vol. 13, no. 8, pp. 1405–1416, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Pavlakis, I. Messini, T. Vrekoussis et al., “The assessment of angiogenesis and fibroblastic stromagenesis in hyperplastic and pre-invasive breast lesions,” BMC Cancer, vol. 8, article 88, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Wülfing, C. Kersting, J. Tio et al., “Endothelin-1-, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancer,” Clinical Cancer Research, vol. 10, no. 7, pp. 2393–2400, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Wülfing, J. Tio, C. Kersting et al., “Expression of endothelin-A-receptor predicts unfavourable response to neoadjuvant chemotherapy in locally advanced breast cancer,” British Journal of Cancer, vol. 91, no. 3, pp. 434–440, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Tsutsui, K. Yasuda, K. Suzuki, K. Tahara, H. Higashi, and S. Era, “Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density,” Oncology Reports, vol. 14, no. 2, pp. 425–431, 2005. View at Google Scholar · View at Scopus
  28. T. Valković, F. Dobrila, M. Melato, F. Sasso, C. Rizzardi, and N. Jonjić, “Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma,” Virchows Archiv, vol. 440, no. 6, pp. 583–588, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. D. C. Chhieng, S. O. Tabbara, E. F. Marley, L. I. Talley, and A. R. Frost, “Microvessel density and vascular endothelial growth factor expression in infiltrating lobular mammary carcinoma,” Breast Journal, vol. 9, no. 3, pp. 200–207, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Zhou, S.-Q. Cheng, H.-F. Ji et al., “Evaluation of protein pigment epithelium-derived factor (PEDF) and microvessel density (MVD) as prognostic indicators in breast cancer,” Journal of Cancer Research and Clinical Oncology, vol. 136, no. 11, pp. 1719–1727, 2010. View at Publisher · View at Google Scholar
  31. M. Thomas and H. G. Augustin, “The role of the angiopoietins in vascular morphogenesis,” Angiogenesis, vol. 12, no. 2, pp. 125–137, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Tsutsui, H. Inoue, K. Yasuda et al., “Angiopoietin 2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density,” Breast Cancer Research and Treatment, vol. 98, no. 3, pp. 261–266, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Min, X. Ren, D. B. Vaught et al., “Tie2 signaling regulates osteoclastogenesis and osteolytic bone invasion of breast cancer,” Cancer Research, vol. 70, no. 7, pp. 2819–2828, 2010. View at Publisher · View at Google Scholar
  34. L. S. Rosen, H. L. Ashurst, and L. Chap, “Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review,” Oncologist, vol. 15, no. 3, pp. 216–235, 2010. View at Publisher · View at Google Scholar
  35. S. Greenberg and H. S. Rugo, “Triple-negative breast cancer: role of antiangiogenic agents,” Cancer Journal, vol. 16, no. 1, pp. 33–38, 2010. View at Publisher · View at Google Scholar
  36. S.-H. Lee, N. Mizutani, M. Mizutani et al., “Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer,” Cancer Immunology, Immunotherapy, vol. 55, no. 12, pp. 1565–1574, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Luo, H. Zhou, M. Mizutani, N. Mizutani, R. A. Reisfeld, and R. Xiang, “Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 15, pp. 8850–8855, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Di Cosimo and J. Baselga, “Management of breast cancer with targeted agents: importance of heterogenicity,” Nature Reviews Clinical Oncology, vol. 7, no. 3, pp. 139–147, 2010. View at Publisher · View at Google Scholar